Skip to main
PSTV

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics is experiencing positive momentum and progress with its clinical trials and commercialization of CNSide. The company is expected to hit key milestones in 2026, especially in regards to its treatments for CNS cancers like GBM and LM. However, there may be risk factors to consider and the company has a history of needing to conduct reverse stock splits, which could create volatility for investors. Overall, with a solid financial position and major contracts in place, the company has the potential for significant upside and growth in the long term.

Bears say

Plus Therapeutics is facing financial struggles, as evidenced by their Q1 2022 results, with only $15 million in cash and $1 million in debt, and recent Q4 results showing EPS of $(1.01). Additionally, While the acquisition of CNSide provides some potential commercial opportunities, the company will not fully ramp up its launch until Q4 of 2026. With limited cash and potential delays in commercialization, Plus Therapeutics will likely face continuing financial challenges, causing a negative outlook for their stock.

PSTV has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 3 analysts, PSTV has a Strong Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.